Complete Mounjaro to Wegovy Switching Guide & Prices
Understanding Mounjaro Equivalent Dose to Wegovy Conversion
When switching from Mounjaro (tirzepatide) to Wegovy (semaglutide), understanding the dose equivalence requires professional medical guidance due to the different mechanisms of action. Mounjaro is a dual GIP and GLP-1 receptor agonist, while Wegovy targets GLP-1 receptors exclusively. Your prescriber will typically assess your current Mounjaro dose and treatment response to determine the appropriate starting Wegovy dose. Most patients transitioning from lower Mounjaro doses may start Wegovy at the 0.25mg dose and follow the standard escalation schedule.
The conversion isn't a direct milligram-for-milligram equivalent, as these medications work through different pathways despite both supporting weight management. Patients switching from Mounjaro's 2.5mg dose might begin Wegovy at 0.25mg, while those on higher Mounjaro doses may start at 0.5mg, though individual circumstances vary significantly. Your EverydayMeds prescriber will evaluate your treatment history, current response, and any side effects experienced to determine the optimal Mounjaro equivalent dose to Wegovy transition plan. This personalised approach ensures continuity of your weight management journey while optimising both safety and effectiveness.
Switch & Save: Wegovy Pricing Advantages
Switching from Mounjaro to Wegovy can offer substantial cost savings, with our Wegovy starter dose at £79.99 compared to typical Mounjaro pricing structures. New customers benefit from code FIRST40, while returning patients use DOSE25, both applied at checkout to reach our competitive final prices. Our complete Wegovy dose escalation includes 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and maintenance 2.4mg (£209.99). For patients planning their full transition, our Intro Trio bundle provides three months of step-up dosing (0.25mg, 0.5mg, 1mg) for £299.99.
The financial benefits of switching to Wegovy extend beyond individual pen prices, particularly when considering our convenient bundle options. Our Progress Duo (0.5mg & 1mg) at £189.99 suits patients starting mid-escalation, while the Consistency ranges offer dual-pen supplies for extended maintenance periods. These pricing structures make the Mounjaro equivalent dose to Wegovy switch financially attractive while maintaining the same high-quality, cold-chain delivery and professional oversight. Calculate your potential annual savings by comparing your current Mounjaro costs against our transparent Wegovy pricing structure.
Clinical Evidence Supporting Mounjaro to Wegovy Transitions
The STEP clinical trial programme demonstrates Wegovy's effectiveness as a standalone weight management treatment, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise. Patients switching from other GLP-1 treatments may maintain their weight management progress, though individual responses vary. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events, supporting Wegovy's broader health benefits beyond weight management.
For patients considering the Mounjaro equivalent dose to Wegovy switch, clinical data suggests both medications offer substantial weight management support through different mechanisms. Wegovy's extensive trial data (Wilding et al., NEJM, 2021) provides robust evidence for its effectiveness across diverse patient populations. Your prescriber will review your Mounjaro treatment response to predict likely outcomes with Wegovy, ensuring the switch aligns with your weight management goals and health profile.
How Wegovy Works After Mounjaro Treatment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Unlike Mounjaro's dual GIP and GLP-1 action, Wegovy focuses exclusively on GLP-1 pathways, which may suit patients who experienced specific side effects with the dual-action approach. The medication works on brain appetite centres to reduce food cravings and helps slow gastric emptying, extending feelings of fullness. This prescription-only medicine requires weekly self-injection using the convenient FlexTouch pen system, maintaining the same injection frequency as Mounjaro. Wegovy must be used alongside a reduced-calorie diet and increased physical activity for optimal weight management results.
Seamless Ordering Process for Switchers
Switching your prescription from Mounjaro to Wegovy through EverydayMeds takes just minutes with our streamlined process designed for existing weight management patients. Complete our 3-minute online clinical assessment, providing details about your current Mounjaro treatment, dose, duration, and any side effects or concerns. Our prescribers review switching requests within 3 working days (24 hours with express service), evaluating your treatment history to determine the appropriate Wegovy starting dose. Once approved, your first Wegovy pen ships via next-day delivery in temperature-controlled packaging, ensuring medication integrity. This efficient process eliminates treatment gaps when switching between weight management medications, maintaining momentum in your health journey.
Storage Advantages When Switching to Wegovy
One practical benefit of the Mounjaro equivalent dose to Wegovy switch involves storage flexibility, as Wegovy remains stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. Store unused Wegovy pens in your fridge at 2-8°C, and once in use, the FlexTouch pen can travel with you for extended periods without refrigeration concerns. The pen delivers precise doses through its simple dial mechanism, with clear dose indicators and an automatic needle safety system. Follow the standard dose escalation schedule starting at 0.25mg weekly, increasing every 4 weeks until reaching your maintenance dose. This extended storage stability particularly benefits frequent travelers or those with limited refrigeration access.
Personalised Switching Strategies for Different Patient Profiles
Patients switching from Mounjaro to Wegovy fall into several categories, each requiring tailored approaches to determine the most appropriate equivalent dose conversion. Those experiencing gastrointestinal side effects with Mounjaro may benefit from Wegovy's single-pathway action, potentially reducing digestive disruption during the transition. Cost-conscious patients often find Wegovy's pricing structure more sustainable long-term, particularly when utilising our bundle options for extended supply security.
Availability-driven switchers, facing Mounjaro supply constraints, can seamlessly transition to Wegovy without interrupting their weight management progress, as both medications support similar therapeutic goals through GLP-1 pathways. The Mounjaro equivalent dose to Wegovy determination considers your previous highest tolerated dose, treatment duration, weight loss response, and any adverse effects experienced. Our clinical team evaluates these factors to recommend whether you should restart at 0.25mg or begin at a higher dose, ensuring optimal outcomes while minimising switching-related complications.
Complete Your Switch to Wegovy Today
Ready to explore the Mounjaro equivalent dose to Wegovy switch with potential cost savings and enhanced storage convenience? Our expert prescribers guide you through the transition process, ensuring safe, effective continuation of your weight management journey. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment, with new customers using code FIRST40 and returning patients applying DOSE25 at checkout for our competitive pricing. Join thousands of patients who've successfully switched their weight management treatments through EverydayMeds' professional, convenient service. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine, properly stored medication with ongoing clinical support throughout your treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
